Bristol-Myers Squibb: Lymphoma, Mantle-Cell trials

The registry lists 12 Lymphoma, Mantle-Cell studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 3Phase 3 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788652
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).TerminatedNCT01021423Phase 3Results posted
• A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00875667Phase 2Results posted
• A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialCompletedNCT00737529Phase 2Results posted
• A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in KoreaCompletedNCT04036448
• A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT03647124
• Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
• Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
• Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib TreatmentCompletedNCT02341781
• Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell LymphomaWithdrawnNCT00730652Phase 1
• MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedNCT00543582Phase 2